Baxalta sales and marketing update

Late last year, Baxalta launched Adynovate in the U.S. to treat hemophilia A. The wholesale acquisition cost (WAC) for Adynovate is $1.98 per 1 IU dose. The recommended dose for routine prophylaxis i...